Zealand Eyes Opportunities In Burgeoning Obesity Market
Boehringer-Partnered Drug Moving Into Phase III Soon
Given the renewed interest in the commercial potential of obesity therapies, Zealand is heralding the potential of its treatments for the overweight.
You may also be interested in...
The partners’ dual GLP-1/GCGR agonist has achieved up to 14.9% weight loss in obese and overweight adults in a mid-stage trial but rival products Wegovy and Mounjaro will likely dominate the space according to analysts.
US approval for its hypoglycemia injection Zegalogue last year has not been converted into commercial success. Zealand will be hoping that having diabetes giant Novo Nordisk onboard will put that right.
Orchard and Zealand are the latest European players to succumb to a financial pinch in the biotech sector, streamlining their pipelines and laying off staff to save on expenses.